Released Feb 10, 2020, after the close
10-K filed Feb 27, 2020, 58 days after period end · 0001162194-20-000016
Q4 2019 · 10-K
Revenue$32.44M$32.44M +0.4% vs Q4 2018+22.4% vs Q3 2019
Net Income-$12.69M-$12.69M derivedN/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.18-$0.18 N/M vs Q4 2018N/M vs Q3 2019
Gross Profit$17,538,000−6.8%
Operating Incomederived-$9,181,000N/M
Operating Cash Flowderived-$5,519,000N/M
Free Cash Flowderived-$6,019,000N/M
Margins · derived
Gross margin54.1%−4.1 pt vs Q4 2018
Operating margin-28.3%+6.1 pt vs Q4 2018
Net margin-39.1%+6.6 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019 | Q4 2018 | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $32.44M | $32.33M | $27.75M | $25.08M |
| Net Income | -$12.69M | -$14.78M | -$10.46M | -$17.70M |
| EPS Diluted | -$0.18 | -$0.36 | -$0.27 | -$0.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR